The database also showed that patients with high CPN1 levels and the pathological classification of basal-like, Estrogen Receptor (ER)-positive, luminal A, luminal B, and wild-type TP53 breast cancer had a shorter overall survival time and poorer prognosis. This evidence concerns the gene CPN1 and breast carcinoma.